LENZ Stock Forecast & Price Target

LENZ Therapeutics is supported by strong early commercial traction in VIZZ, with Q3 sales of $2.6MM and 38K+ paid prescriptions, reflecting 53% quarter-over-quarter sales growth and rising awareness in a large presbyopia market. Its differentiated aceclidine, pupil-selective mechanism, once-daily convenience, and durable near-vision benefit of up to 10 hours appear to be resonating with prescribers, while telehealth and ePharmacy now drive more than 50% of incremental prescriptions and over 60% of patients have bought more than one monthly pack. The company’s strategic reorganization also improves the investment case, as projected 2027 annualized operating expenses are expected to fall by more than 50% versus prior assumptions, helping extend runway while consumer marketing and repeat prescribing scale.

LENZ Therapeutics is viewed negatively because 3Q26 revenue of $3.4M missed both consensus of $4.2M and the $6.0M estimate, while SG&A reached $35.8M and the company posted a $31.0M net loss, or $0.99 per diluted share. Weak Symphony-reported Rx trends forced a cut in VIZZ sales expectations to $2.5M from $4.0M for 3Q and to $10M from $15M for FY26, signaling slower-than-expected commercial traction despite management efforts to drive awareness. Investor concerns are further amplified by retinal detachment risk commentary, limited long-term safety and efficacy data, and ongoing clinical, regulatory, and competitive uncertainty, even with $197.3M in cash and equivalents as of September 30, 2026.